Evidence map›Paper›PMID 36479247›Full record

ArticleFrontiers in genetics2022

Genomic profiling and network-level understanding uncover the potential genes and the pathways in hepatocellular carcinoma.

Sherif A El-Kafrawy, Mai M El-Daly, Leena H Bajrai, Thamir A Alandijany, Arwa A Faizo, Mohammad Mobashir, Sunbul S Ahmed, Sarfraz Ahmed, Shoaib Alam, Raja Jeet and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 5 countries.

Sherif A El-KafrawySpecial Infectious Agents Unit-BSL3, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
Mai M El-DalySpecial Infectious Agents Unit-BSL3, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
Leena H BajraiSpecial Infectious Agents Unit-BSL3, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
Thamir A AlandijanySpecial Infectious Agents Unit-BSL3, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
Arwa A FaizoSpecial Infectious Agents Unit-BSL3, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammad MobashirDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, Stockholm, Sweden.
Sunbul S AhmedGenome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
Sarfraz AhmedDepartment of Biosciences, Jamia Millia Islamia, New Delhi, India.
Shoaib AlamDepartment of Biotechnology, Jamia Millia Islamia, New Delhi, India.
Raja JeetBotany Department, Ganesh Dutt College, Begusarai, Bihar, India.
Mohammad Amjad KamalInstitutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Syed Tauqeer AnwerGenome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
Bushra KhanGenome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
Manal TashkandiDepartment of Biochemistry, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Moshahid A RizviGenome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
Esam Ibraheem AzharSpecial Infectious Agents Unit-BSL3, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
King Abdulaziz University · SAJamia Millia Islamia · INDepartment of Biotechnology · INJeddah University · SAKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data integration with phenotypes such as gene expression, pathways or function, and protein-protein interactions data has proven to be a highly promising technique for improving human complex diseases, particularly cancer patient outcome prediction. Hepatocellular carcinoma is one of the most prevalent cancers, and the most common cause is chronic HBV and HCV infection, which is linked to the majority of cases, and HBV and HCV play a role in multistep carcinogenesis progression. We examined the list of known hepatocellular carcinoma biomarkers with the publicly available expression profile dataset of hepatocellular carcinoma infected with HCV from day 1 to day 10 in this study. The study covers an overexpression pattern for the selected biomarkers in clinical hepatocellular carcinoma patients, a combined investigation of these biomarkers with the gathered temporal dataset, temporal expression profiling changes, and temporal pathway enrichment following HCV infection. Following a temporal analysis, it was discovered that the early stages of HCV infection tend to be more harmful in terms of expression shifting patterns, and that there is no significant change after that, followed by a set of genes that are consistently altered. PI3K, cAMP, TGF, TNF, Rap1, NF-kB, Apoptosis, Longevity regulating pathway, signaling pathways regulating pluripotency of stem cells, Cytokine-cytokine receptor interaction, p53 signaling, Wnt signaling, Toll-like receptor signaling, and Hippo signaling pathways are just a few of the most commonly enriched pathways. The majority of these pathways are well-known for their roles in the immune system, infection and inflammation, and human illnesses like cancer. We also find that ADCY8, MYC, PTK2, CTNNB1, TP53, RB1, PRKCA, TCF7L2, PAK1, ITPR2, CYP3A4, UGT1A6, GCK, and FGFR2/3 appear to be among the prominent genes based on the networks of genes and pathways based on the copy number alterations, mutations, and structural variants study.

Indexed as

biomarkersco-expressiongene expression/mutational profilingHCV and HCCnetwork-level understanding

Identifiers

PMID36479247
PMCPMC9720179
OpenAlexW4309739677

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.